Problem
How concentrated is the stimulant ADHD medication market, and at what geographic resolution can that question be answered responsibly?
Context
A proposed Florida Medicaid study connecting product-level utilization with market structure. Geographic attribution must be supported by the dataset, rather than inferred from a state-level total.
Dataset
Candidate inputs include public Medicaid State Drug Utilization Data, drug identifiers, product classifications, and independently validated geographic files. No source dataset has been ingested into this demonstration.
Methodology
Define the drug-class inclusion rules; reconcile NDC identifiers; calculate product shares and concentration measures; compare periods; evaluate sensitivity to aggregation and suppression.
Analysis
Concentration can be summarized with the Herfindahl–Hirschman Index (HHI), calculated as the sum of squared shares. Product, manufacturer, and geography are separate analytical dimensions and should not be conflated.
An illustrative analytical view.
Synthetic values illustrate the method only. No real geographic, financial, plan, or utilization result is represented.
Findings
No empirical findings are asserted. The demonstration compares synthetic market-share distributions to show how concentration changes with market structure.
Limitations
State-level utilization does not establish county-level dispensing. Suppressed records, reporting lags, identifier changes, and reimbursement definitions may affect interpretation.
Decision Implications
Inform which markets or segments warrant closer investigation, subject to adequate geographic attribution and validated source coverage.